In-silico evidence for PMTA, explained
Method guides and policy explainers on computing FDA §1114.7 supporting evidence — ELCR, in-silico PK and PHIA — before you commit to clinical spend.
Core method & policy
In-Silico Evidence for PMTA: Modeling ELCR, PK and PHIA Before You File
A pillar guide to the three computable PMTA evidence elements — ELCR, in-silico PK and PHIA — and how each maps to a specific 21 CFR §1114.7 requirement.
How to Generate PMTA Supporting Evidence Without a Full Clinical Trial
Three computable substitutes — in-silico PK, ELCR and PHIA — that generate early-stage PMTA evidence before you commit to CRO clinical spend.
How to Calculate ELCR (Excess Lifetime Cancer Risk) from HPHCs for FDA
The ELCR calculation chain: from measured HPHC concentrations, through a corrected OEHHA/EPA IRIS/IARC IUR library, to Σ ELCR as a percentage of the 1R6F reference.
In-Silico PK for PMTA: Running a 500-Subject Monte Carlo Virtual Trial
How an in-silico PK trial estimates Cmax, Tmax and AUC with a 5–95% prediction interval over a 500-subject Monte Carlo cohort, grounded in Benowitz 2009 PopPK.
PHIA Explained: Population Health Impact Assessment with Markov Models
How a 5/6-state Markov PHIA model over a 50–75 year horizon returns PDA, LYG and an adoption ratio, with dual tipping-point sensitivity for the youth-initiation counterweight.
What Does a PMTA Cost? And How to Reduce It at the Formula-Screening Stage
Where PMTA cost hides — CRO clinical PK, tox review, health-economics consulting — and how in-silico screening cuts it by ranking formulas before clinical spend.
FDA's Move Toward New Approach Methodologies (NAMs): What It Means for Tobacco Applicants
How NAMs, MIDD, ICH M15 and NMPA's 2020 model-informed guidance converge to open a documented, defensible pathway for modeled PMTA supporting evidence.
Understanding FDA §1114.7: What a PMTA-Ready Report Must Contain
What a §1114.7-aligned evidence package includes: toxicology (ELCR), PK, population impact (PHIA), traceable citations and an all-English deliverable.
Passing PMTA Acceptance & Filing Review: The Stage Most Applications Stumble
Acceptance and filing review is the threshold gate where many PMTAs stall. What helps a file clear it: completeness, §1114.7 formatting, traceable sourcing and internal consistency.
The 1R6F Reference Cigarette: Why It Anchors Your ELCR Comparison
Why toxicological metrics like ELCR are expressed relative to the 1R6F reference cigarette — and how the MGO ENDS median adds a second, market-anchored benchmark.
Deep-dive & application
CYP2A6 and Nicotine Metabolism: Why Metabolizer Phenotype Drives Your PK Results
CYP2A6 activity is the single largest driver of nicotine PK variability — which is why a credible in-silico PK trial models the phenotype distribution explicitly.
Monte Carlo vs. Bootstrap: How Uncertainty Is Quantified in a Virtual PK Trial
Two techniques give a virtual PK trial its credibility: Monte Carlo to generate the subject population, and bootstrap resampling to put a 90% confidence interval on the summary statistics.
HPHC Testing to Evidence: Turning Your Lab Results into a §910(b) Package
The conversion path from measured HPHC concentrations to a §1114.7-formatted §910(b) toxicological section — in minutes, using lab data you already hold.
Weight-of-Evidence Submissions: How Modeled and Empirical Data Combine in a PMTA
FDA weighs the totality of evidence. Understanding weight-of-evidence keeps modeling in its powerful place: it strengthens the file and drafts the evidence spine without replacing confirmatory work.
Nicotine Pouches vs. ENDS: How PMTA Evidence Requirements Differ
Pouches and ENDS both need a PMTA, but the evidence emphasis shifts: HPHC profile, PK absorption route and PHIA behavioral inputs all change by product class.
Data Sovereignty in Regulatory Submissions: Why In-Browser Modeling Keeps Your Formula Private
Your formula is your most valuable IP. In-browser modeling processes HPHC and formulation inputs entirely on your device — no CRO handoff, no vendor cloud — while still exporting a §1114.7 report.
Dual-Track Strategy: Preparing Evidence for FDA PMTA and NMPA at Once
Chinese exporters face FDA and NMPA at once. Building evidence once against both frameworks — with bilingual guidance and an all-English FDA deliverable — is the efficient path.
The MGO ENDS Median: Benchmarking Your Product Against Already-Authorized Products
Beyond the 1R6F cigarette, reviewers want to know how your product compares to ENDS that already cleared the PMTA gate. That second, market-anchored benchmark is the MGO ENDS median.
Youth-Initiation Sensitivity in PHIA: Modeling FDA's Biggest Counterweight
FDA weighs the benefit to adult smokers who switch against the risk of drawing youth into nicotine. A credible PHIA models both, via dual tipping-point sensitivity presented as a range.
A 90-Day Roadmap: From Formula Screening to a §1114.7 Evidence Package
A realistic 90-day sequence that front-loads modeling — ELCR screening, in-silico PK, PHIA — and reserves empirical spend for the surviving formula.